Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 13, Issue 12, Pages 1265-1273
Publisher
Informa UK Limited
Online
2017-11-15
DOI
10.1080/17425255.2017.1405934
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion
- (2017) Katherine S. Virgo et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Should We Try Antiandrogen Withdrawal in Castration-Resistant Prostate Cancer Patients? Insights From a Retrospective Study
- (2016) Hiroshi Hongo et al. Clinical Genitourinary Cancer
- Prostate Cancer, Version 1.2016
- (2016) James L. Mohler et al. Journal of the National Comprehensive Cancer Network
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review
- (2015) Frank Kunath et al. BJU INTERNATIONAL
- Targeting molecular resistance in castration-resistant prostate cancer
- (2015) Thenappan Chandrasekar et al. BMC Medicine
- Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
- (2015) Christopher Sejong Han et al. Expert Opinion on Drug Metabolism & Toxicology
- Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer
- (2015) Laurence Klotz Expert Opinion on Drug Metabolism & Toxicology
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
- (2014) MarkN Stein et al. ASIAN JOURNAL OF ANDROLOGY
- Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer
- (2014) Niels Eckstein et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Diethylstilboestrol for the treatment of prostate cancer: past, present and future
- (2013) Rafal Turo et al. Scandinavian Journal of Urology
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer
- (2009) Lockwood G. Taylor et al. CANCER
- Degarelix
- (2009) James E. Frampton et al. DRUGS
- Antiandrogen withdrawal in castrate-refractory prostate cancer
- (2008) A. Oliver Sartor et al. CANCER
- Androgen deprivation therapy for prostate cancer
- (2008) Eric A Singer et al. EXPERT OPINION ON PHARMACOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started